title: β2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS).
abstract: Amyotrophic lateral sclerosis (ALS) is a chronic and progressive neuromuscular disease for which no cure exists and better treatment options are desperately needed. We hypothesize that currently approved β2-adrenoceptor agonists may effectively treat the symptoms and possibly slow the progression of ALS. Although β2-agonists are primarily used to treat asthma, pharmacologic data from animal models of neuromuscular diseases suggest that these agents may have pharmacologic effects of benefit in treating ALS. These include inhibiting protein degradation, stimulating protein synthesis, inducing neurotrophic factor synthesis and release, positively modulating microglial and systemic immune function, maintaining the structural and functional integrity of motor endplates, and improving energy metabolism. Moreover, stimulation of β2-adrenoceptors can activate a range of downstream signaling events in many different cell types that could account for the diverse array of effects of these agents. The evidence supporting the possible therapeutic benefits of β2-agonists is briefly reviewed, followed by a more detailed review of clinical trials testing the efficacy of β-agonists in a variety of human neuromuscular maladies. The weight of evidence of the potential benefits from treating these diseases supports the hypothesis that β2-agonists may be efficacious in ALS. Finally, ways to monitor and manage the side effects that may arise with chronic administration of β2-agonists are evaluated. In sum, effective, safe and orally-active β2-agonists may provide a novel and convenient means to reduce the symptoms of ALS and possibly delay disease progression, affording a unique opportunity to repurpose these approved drugs for treating ALS, and rapidly transforming the management of this serious, unmet medical need.
authors.affiliation: RTBioconsultants, Inc., San Diego, CA 92130, United States. Electronic address: bartus@RTBioconsultants.com.
authors.forename: Raymond T
authors.initials: RT
authors.lastname: Bartus
authors.affiliation: Above and Beyond, LLC, Atlanta, GA, United States.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Bétourné
authors.affiliation: Independent Consultant, Carlsbad, CA, United States.
authors.forename: Anthony
authors.initials: A
authors.lastname: Basile
authors.affiliation: Above and Beyond, LLC, Atlanta, GA, United States.
authors.forename: Bethany L
authors.initials: BL
authors.lastname: Peterson
authors.affiliation: Dept Neurology and Emory ALS Center, Emory University School of Medicine, Atlanta, GA, United States.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Glass
authors.affiliation: Dept Neurosurgery, Emory University School of Medicine, Atlanta, GA, United States.
authors.forename: Nicholas M
authors.initials: NM
authors.lastname: Boulis
mesh_terms: D000284:Administration, Oral; D058666:Adrenergic beta-2 Receptor Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D006801:Humans; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D018696:Neuroprotective Agents
keywords: ALS; Anabolic muscle effects; Motor neuron degeneration; Neuromuscular disease; Neuromuscular junction; Neuroprotection; Neurorestoration; Repurposing drugs; β(2)-Adrenoceptor agonists